Introduction: Bronchial thermoplasty (BT) improves asthma-related quality of life and decreases the number of asthma exacerbations. However, the effectiveness of BT in the treatment of severe asthma with smoking history is unclear because previous studies have excluded patients with smoking history of more than 10 pack-years. Objective: The aim of the study was to clarify the effectiveness and safety of BT for severe asthma with smoking history. Methods: We retrospectively reviewed patients who received BT and compared its effectiveness and safety with and without smoking history. Results: Seven patients were assigned to the smoking group and 9 to the nonsmoking group. Before BT, despite Global Initiative for Asthma step 4 or 5 treatment including oral corticosteroids (OCS) or monoclonal antibody drugs, most patients in both groups had asthma-related symptoms every day (85.7 vs. 77.8%; p = 0.475) and frequent asthma exacerbations. After BT, in the smoking group, 3 patients could discontinue or reduce OCS and all 3 patients treated with monoclonal antibody drugs could discontinue them. In the smoking group, 6 patients (85.7%) experienced a reduction in the rate of symptoms, of which 3 patients (42.9%) had a disappearance of symptoms, similar to the nonsmoking group. BT was effective in 5 patients (83.3%) in the smoking group and 6 patients (75.0%) in the nonsmoking group. There were no severe complications. Conclusions: BT was found to be effective and safe for treatment of severe asthma with smoking history. Our results suggest that BT may be a therapeutic option for asthma-chronic obstructive pulmonary disease overlap.
Int Arch Allergy Immunol

中文翻译：

---

支气管热成形术治疗严重哮喘和吸烟史的有效性和安全性：单中心经验。

简介：支气管热成形术（BT）可改善与哮喘有关的生活质量，并减少哮喘加重的次数。然而，由于先前的研究已经排除了吸烟史超过10包年的患者，因此BT在治疗具有吸烟史的严重哮喘中的有效性尚不清楚。目的：本研究旨在阐明BT对患有吸烟史的严重哮喘的有效性和安全性。方法：我们回顾性分析了接受BT治疗的患者，并比较了有无吸烟史的BT有效性和安全性。结果：七名患者被分为吸烟组，九名患者被分为非吸烟组。在BT之前，尽管有全球哮喘倡议的第4或5步治疗方案（包括口服皮质类固醇（OCS）或单克隆抗体药物），两组中的大多数患者每天仍出现与哮喘有关的症状（85.7 vs. 77.8％；p= 0.475）和频繁的哮喘发作。BT后，在吸烟组中，有3例患者可以停用或降低OCS，并且所有3名接受单克隆抗体药物治疗的患者都可以停用它们。在吸烟组中，有6例患者（85.7％）的症状发生率降低了，其中3例（42.9％）的症状消失了，与不吸烟组相似。吸烟组中BT有效5例（83.3％），非吸烟组6例（75.0％）。没有严重的并发症。结论： BT被发现对于治疗有吸烟史的严重哮喘是有效和安全的。我们的结果表明，BT可能是哮喘-慢性阻塞性肺疾病重叠的一种治疗选择。
Int Arch过敏免疫